信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01801 信达生物

已收盘 03-02 16:08:34

82.600

-2.500

-2.94%

最高85.100	最低81.500	成交量1,028万
今开85.100	昨收85.100	日振幅4.23%
总市值1,433亿	流通市值1,433亿	总股本17.35亿
成交额8.49亿	换手率0.59%	流通股本17.35亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":82.6,"timestamp":1772438914004,"preClose":85.1,"halted":0,"volume":10275411,"delay":0,"changeRate":-0.029377203290246772,"floatShares":1735000000,"shares":1735000000,"eps":-0.06820513622816556,"marketStatus":"已收盘","change":-2.5,"latestTime":"03-02 16:08:34","open":85.1,"high":85.1,"low":81.5,"amount":849043905,"amplitude":0.042303,"askPrice":82.6,"askSize":107500,"bidPrice":82.55,"bidSize":500,"shortable":3,"etf":0,"ttmEps":0.7669258338039848,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772501400000},"marketStatusCode":5,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":85.1,"openAndCloseTimeList":[[1772415000000,1772424000000],[1772427600000,1772438400000]],"volumeRatio":0.966095,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.468,"impliedVolPercentile":0.1748},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"2616238978","title":"信达生物盘中异动 早盘快速下挫3.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616238978","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616238978?lang=zh_cn&edition=full","pubTime":"2026-03-02 09:51","pubTimestamp":1772416285,"startTime":"0","endTime":"0","summary":"2026年03月02日早盘09时51分，信达生物股票出现异动，股价快速下跌3.00%。截至发稿，该股报82.550港元/股，成交量219.91万股，换手率0.13%，振幅3.00%。机构评级方面，在所有25家参与评级的机构中，88%的券商给予买入建议，12%的券商给予持有建议，无券商给予卖出建议。信达生物股票所在的药品行业中，整体跌幅为0.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603020951259542849b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603020951259542849b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","LU2097828557.USD","LU2097828714.EUR","HK0000165453.HKD","LU2097828631.EUR","LU0502904849.HKD","LU2097828474.EUR","LU2097828805.USD","LU2488822045.USD","BK1161","01801","BK1583","LU2328871848.SGD","BK1589","LU0455707207.USD","LU2242644610.SGD"],"gpt_icon":0},{"id":"1177264253","title":"Jaypirca®（Pirtobrutinib）在中国获批用于治疗复发或难治性慢性淋巴细胞白血病或小淋巴细胞淋巴瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1177264253","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177264253?lang=zh_cn&edition=full","pubTime":"2026-03-02 08:00","pubTimestamp":1772409611,"startTime":"0","endTime":"0","summary":"Jaypirca®（Pirtobrutinib）已在中国获得批准，用于治疗复发或难治性慢性淋巴细胞白血病（CLL）或小淋巴细胞淋巴瘤（SLL）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828714.EUR","LU2328871848.SGD","HK0000165453.HKD","BK1589","LU1969619763.USD","BK1583","LU2097828557.USD","LU0455707207.USD","LU2097828474.EUR","LU2097828805.USD","01801","LU2488822045.USD","LU2097828631.EUR","BK1161","LU2242644610.SGD","LU0502904849.HKD"],"gpt_icon":0},{"id":"2614148888","title":"信达生物玛仕度肽注射液启动III期临床 适应症为高血压合并超重/肥胖人群的血压控制","url":"https://stock-news.laohu8.com/highlight/detail?id=2614148888","media":"新浪财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614148888?lang=zh_cn&edition=full","pubTime":"2026-02-28 18:03","pubTimestamp":1772272980,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，信达生物制药（苏州）有限公司的玛仕度肽注射液一项在未接受降压药治疗的轻、中度高血压合并超重/肥胖的参与者中评估IBI362有效性和安全性的多中心、随机、双盲、安慰剂对照临床研究已启动。玛仕度肽注射液为化学药物，适应症为高血压合并超重/肥胖人群的血压控制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260228185958a72a562d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260228185958a72a562d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0455707207.USD","HK0000165453.HKD","BK1583","BK1589","LU1969619763.USD","LU2097828474.EUR","LU2097828805.USD","LU2488822045.USD","01801","LU2328871848.SGD","BK1161","LU2097828714.EUR","LU2097828631.EUR","LU2242644610.SGD","LU0502904849.HKD","LU2097828557.USD"],"gpt_icon":0},{"id":"2614110038","title":"破解BTK抑制剂耐药困局！信达生物捷帕力®在中国获批CLL/SLL新适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2614110038","media":"药渡Daily","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614110038?lang=zh_cn&edition=full","pubTime":"2026-02-28 17:56","pubTimestamp":1772272595,"startTime":"0","endTime":"0","summary":"随着共价BTK抑制剂在国内广泛应用，耐药后患者的治疗需求日益迫切。此次匹妥布替尼CLL/SLL适应症的获批，填补了中国市场在这一领域的关键空白。信达生物表示，将充分发挥在肿瘤领域的领先品牌和专业化能力，加速匹妥布替尼新适应症的市场准入，尽快惠及更多亟需治疗的CLL/SLL患者。2024年10月在中国获批MCL适应症，如今CLL/SLL适应症再下一城。在信达生物的商业化推动下，中国的CLL/SLL患者即将迎来这一全球创新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022818424497a76e0f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022818424497a76e0f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU0455707207.USD","LU2242644610.SGD","LU2097828631.EUR","HK0000165453.HKD","LU2097828714.EUR","LU2488822045.USD","BK1589","LU1969619763.USD","LU2097828474.EUR","LU2097828557.USD","BK1583","01801","LU0502904849.HKD","LU2328871848.SGD","LU2097828805.USD"],"gpt_icon":0},{"id":"2614811008","title":"信达生物：TOP1i/MMAE双抗双毒素ADC启动493例一期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2614811008","media":"医药笔记","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614811008?lang=zh_cn&edition=full","pubTime":"2026-02-28 08:19","pubTimestamp":1772237996,"startTime":"0","endTime":"0","summary":"▎Armstrong2026年2月27日，信达生物在药物临床试验登记与信息公示平台注册了IBI3028治疗晚期实体瘤的一期临床试验。该一期临床计划入组493例晚期实体瘤患者。信达生物围绕ADC进行了系统性布局，建立了三个技术平台，分别为SystecanE技术平台、SoloTx技术平台、DuetTx双毒素技术平台。根据临床注册信息，可知IBI3028采用TOP1i/MMAE为payload。信达生物已有多款双靶点ADC进入临床阶段，双毒素ADC也开始陆续进入临床阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022808533897a75d5a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022808533897a75d5a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1589","LU0455707207.USD","LU1969619763.USD","LU2097828631.EUR","HK0000165453.HKD","LU2328871848.SGD","LU2097828805.USD","LU2097828474.EUR","BK1161","LU2097828714.EUR","LU2242644610.SGD","01801","LU0502904849.HKD","LU2488822045.USD","LU2097828557.USD"],"gpt_icon":0},{"id":"2614378830","title":"信达生物(01801)：捷帕力®(匹妥布替尼)在中国获批复发或难治性慢性淋巴细胞白血病或小淋巴细胞淋巴瘤适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2614378830","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614378830?lang=zh_cn&edition=full","pubTime":"2026-02-27 19:38","pubTimestamp":1772192316,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物 发布公告，非共价(可逆)布鲁顿酪氨酸激酶抑制剂捷帕力正式获得中国国家药品监督管理局批准新增适应症，用于治疗既往经过至少包含BTK抑制剂在内的一种系统治疗的成人慢性淋巴细胞白血病╱小淋巴细胞淋巴瘤患者。2024年10月，匹妥布替尼在中国获批，单药适用于既往接受过至少两种系统性治疗的复发或难治性套细胞淋巴瘤成人患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408361.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828805.USD","LU0502904849.HKD","LU2242644610.SGD","LU2097828631.EUR","HK0000165453.HKD","LU2097828557.USD","LU2097828474.EUR","BK1589","LU2488822045.USD","LU1969619763.USD","01801","LU2097828714.EUR","LU0455707207.USD","LU2328871848.SGD","BK1583","BK1161"],"gpt_icon":0},{"id":"2614869942","title":"产业焦点 | 首批司美格鲁肽仿制药临近上市，减重药将迎“白菜价”时代","url":"https://stock-news.laohu8.com/highlight/detail?id=2614869942","media":"第一财经陆家嘴","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614869942?lang=zh_cn&edition=full","pubTime":"2026-02-27 17:12","pubTimestamp":1772183522,"startTime":"0","endTime":"0","summary":"导语随着更多仿制药的上市，减重药很快就会迎来“白菜价”时代。此前，诺和诺德的司美格鲁肽以及礼来的替尔泊肽用于糖尿病适应症的药物在被纳入医保后，价格都大幅“跳水”。该公司日前公告称，司美格鲁肽生物类似药吉可亲上市申请已获中国国家药监局正式受理，本次申报的适应症为肥胖或超重人群的体重管理。所谓的参考药物，就是诺和诺德的司美格鲁肽减重药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227190513a4371418&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227190513a4371418&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU0455707207.USD","LU2242644610.SGD","LU2097828631.EUR","HK0000165453.HKD","LU2097828714.EUR","LU2488822045.USD","BK1589","LU1969619763.USD","LU2097828474.EUR","LU2097828557.USD","BK1583","01801","LU0502904849.HKD","LU2328871848.SGD","LU2097828805.USD"],"gpt_icon":0},{"id":"2614699608","title":"信达生物02月27日获主力加仓1762.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614699608","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614699608?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:15","pubTimestamp":1772180147,"startTime":"0","endTime":"0","summary":"02月27日, 信达生物股价涨0.89%，报收85.10元，成交金额10.6亿元，换手率0.72%，振幅4.45%，量比1.33。信达生物今日主力资金净流入1762.1万元，连续7日净流入，上一交易日主力净流入2514.0万元。该股近5个交易日下跌6.94%，主力资金累计净流入9696.1万元；近20日主力资金累计净流入3.4亿元，其中净流入天数为15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227161912a4cefd1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227161912a4cefd1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0502904849.HKD","LU2097828474.EUR","LU2097828557.USD","HK0000165453.HKD","01801","BK1161","BK1589","LU0455707207.USD","LU2097828631.EUR","LU2097828714.EUR","LU2097828805.USD","LU2328871848.SGD","LU2488822045.USD","LU2242644610.SGD","BK1583","LU1969619763.USD"],"gpt_icon":0},{"id":"2614156940","title":"每日卖空追踪 | 信达生物 02月26日卖空量成交93.95万股，卖空比例为8.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614156940","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614156940?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:30","pubTimestamp":1772094625,"startTime":"0","endTime":"0","summary":"信达生物北京时间02月26日，跌4.58%，卖空量成交93.95万股，较上一交易日减少64.85%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226163318a7219a1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226163318a7219a1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828805.USD","LU0502904849.HKD","LU2242644610.SGD","LU2097828631.EUR","HK0000165453.HKD","LU2097828557.USD","LU2097828474.EUR","BK1589","LU2488822045.USD","LU1969619763.USD","01801","LU2097828714.EUR","LU0455707207.USD","LU2328871848.SGD","BK1583","BK1161"],"gpt_icon":0},{"id":"2614015629","title":"信达生物盘中异动 下午盘急速下跌3.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614015629","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614015629?lang=zh_cn&edition=full","pubTime":"2026-02-26 14:52","pubTimestamp":1772088742,"startTime":"0","endTime":"0","summary":"2026年02月26日下午盘14时52分，信达生物股票出现波动，股价急速下跌3.00%。截至发稿，该股报85.750港元/股，成交量690.767万股，换手率0.40%，振幅4.58%。资金方面，该股资金流入2.49711亿港元，流出3.05446亿港元。机构评级方面，在所有25家参与评级的机构中，88%的券商给予买入建议，12%的券商给予持有建议，无券商给予卖出建议。信达生物股票所在的药品行业中，整体跌幅为1.22%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226145222a4ca4c5c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226145222a4ca4c5c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1589","LU0455707207.USD","LU1969619763.USD","LU2097828631.EUR","HK0000165453.HKD","LU2328871848.SGD","LU2097828805.USD","LU2097828474.EUR","BK1161","LU2097828714.EUR","LU2242644610.SGD","01801","LU0502904849.HKD","LU2488822045.USD","LU2097828557.USD"],"gpt_icon":0},{"id":"2614746489","title":"没有“熟果”、主打“开荒”？信达生物超88亿美元BD，不走常规路","url":"https://stock-news.laohu8.com/highlight/detail?id=2614746489","media":"Ofweek光电信息网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614746489?lang=zh_cn&edition=full","pubTime":"2026-02-24 15:42","pubTimestamp":1771918920,"startTime":"0","endTime":"0","summary":"根据协定条款，信达生物将获得3.5亿美元首付款，在达成后续特定里程碑事件后，还有资格获得总额最高约85亿美元的研发、监管及商业化里程碑付款。消息一出，资本市场反响热烈，信达生物股价一度大涨超7%。此次信达生物与礼来的合作更是没有走“老路”，而是倾向于“一起开荒种树苗”模式。因此，信达生物与礼来的BD合作，本质是双方各取所长的深化布局。当然，不可否认的是，目前信达生物的BD出海模式也存在一些潜在问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224154759a718e97c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224154759a718e97c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","BK1161","LU2097828474.EUR","LU2328871848.SGD","HK0000165453.HKD","01801","LU2097828631.EUR","BK1589","LU2097828805.USD","LU2097828557.USD","LU0455707207.USD","LU2097828714.EUR","BK1583","LU0502904849.HKD","LU1969619763.USD","LU2242644610.SGD"],"gpt_icon":0},{"id":"2614746805","title":"【券商聚焦】海通国际：香港医疗板块情绪回暖 看好创新药龙头信达生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2614746805","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614746805?lang=zh_cn&edition=full","pubTime":"2026-02-24 11:29","pubTimestamp":1771903764,"startTime":"0","endTime":"0","summary":"金吾财讯|海通国际发布研报指，香港医疗保健板块本周表现强劲，恒生医疗保健指数上涨3.2%，跑赢恒生指数3.2个百分点。板块回暖主要受信达生物与礼来达成88.5亿美元战略合作催化，该交易创下中国创新药企BD新纪录。信达生物将获得3.5亿美元首付款及最高85亿美元里程碑付款，保留大中华区权益，凸显其研发能力获国际认可。海通国际维持对信达生物、药明生物等创新药产业链龙头的\"优于大市\"评级，认为中国创新药企全球化能力持续提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224114823a4c13dac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224114823a4c13dac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828557.USD","BK1161","LU2097828474.EUR","LU2097828805.USD","LU0502904849.HKD","LU2097828714.EUR","BK1583","HK0000165453.HKD","06978","02252","BK1617","LU2328871848.SGD","BK1589","LU2242644610.SGD","01801","LU2488822045.USD","LU0455707207.USD","LU2097828631.EUR","LU1969619763.USD","02269","BK1100","BK1574"],"gpt_icon":0},{"id":"2613845768","title":"信达生物盘中异动 急速跳水3.04%报89.200港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613845768","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613845768?lang=zh_cn&edition=full","pubTime":"2026-02-24 10:34","pubTimestamp":1771900477,"startTime":"0","endTime":"0","summary":"2026年02月24日早盘10时34分，信达生物股票出现波动，股价快速下挫3.04%。截至发稿，该股报89.200港元/股，成交量470.098万股，换手率0.27%，振幅4.35%。资金方面，该股资金流入1.22438亿港元，流出1.87528亿港元。机构评级方面，在所有24家参与评级的机构中，88%的券商给予买入建议，12%的券商给予持有建议，无券商给予卖出建议。信达生物股票所在的药品行业中，整体跌幅为0.35%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022410343797a6c6fd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022410343797a6c6fd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","LU0455707207.USD","BK1589","LU2242644610.SGD","LU1969619763.USD","LU2097828631.EUR","LU0502904849.HKD","LU2488822045.USD","LU2097828714.EUR","LU2097828805.USD","01801","LU2097828474.EUR","HK0000165453.HKD","BK1161","LU2328871848.SGD","LU2097828557.USD"],"gpt_icon":0},{"id":"2613768863","title":"成为MNC还是CRO，中国新药需要选择吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2613768863","media":"盖德化工网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613768863?lang=zh_cn&edition=full","pubTime":"2026-02-24 08:02","pubTimestamp":1771891327,"startTime":"0","endTime":"0","summary":"Guide View成为MNC还是CRO，这是2月份在新药领域引发争议的一个话题。Guide View面对上述担忧，更多的人士认为，随着多元合作模式的探索落地，国产新药自主全球化提速，成为MNC还是CRO，不是中国新药需要做的一项选择题。结语Guide View种种迹象说明，成为MNC还是CRO不会是中国新药的一道选择题，中国新药具备广阔的兼容性，技术与效率驱动时代，可以多条腿走路探索，多数boitech的务实需求是先赚钱后谈梦想，少数Biopharma却会先成为种子，等待长成参天大树的那天。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224080919a717553d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224080919a717553d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828805.USD","HK0000165453.HKD","LU2097828631.EUR","BK1583","LU2097828474.EUR","LU2488822045.USD","LU1969619763.USD","01801","LU2097828557.USD","LU2328871848.SGD","02196","LU2097828714.EUR","LU2242644610.SGD","BK1589","BK1161","01093","LU0455707207.USD","LU0502904849.HKD"],"gpt_icon":0},{"id":"2613846787","title":"每日卖空追踪 | 信达生物 02月23日卖空量成交62.45万股，卖空比例为12.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613846787","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613846787?lang=zh_cn&edition=full","pubTime":"2026-02-23 16:30","pubTimestamp":1771835425,"startTime":"0","endTime":"0","summary":"信达生物北京时间02月23日，涨1.38%，卖空量成交62.45万股，较上一交易日减少65.75%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163252a4be7ccf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163252a4be7ccf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0502904849.HKD","LU2097828474.EUR","LU2097828557.USD","HK0000165453.HKD","01801","BK1161","BK1589","LU0455707207.USD","LU2097828631.EUR","LU2097828714.EUR","LU2097828805.USD","LU2328871848.SGD","LU2488822045.USD","LU2242644610.SGD","BK1583","LU1969619763.USD"],"gpt_icon":0},{"id":"2613878387","title":"信达生物02月23日获主力加仓1682.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613878387","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613878387?lang=zh_cn&edition=full","pubTime":"2026-02-23 16:15","pubTimestamp":1771834521,"startTime":"0","endTime":"0","summary":"02月23日, 信达生物股价涨1.38%，报收92.00元，成交金额4.8亿元，换手率0.30%，振幅2.26%，量比0.59。信达生物今日主力资金净流入1682.5万元，连续3日净流入，上一交易日主力净流入2004.0万元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为65.00%，平均涨幅为4.46%。该股近5个交易日上涨2.62%，主力资金累计净流入5658.9万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入9925.7万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223161607a4be70a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223161607a4be70a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01801","LU2097828714.EUR","LU2488822045.USD","LU2097828474.EUR","LU2097828557.USD","LU1969619763.USD","LU2328871848.SGD","BK1583","BK1589","LU2097828805.USD","LU2242644610.SGD","LU0502904849.HKD","HK0000165453.HKD","LU0455707207.USD","LU2097828631.EUR"],"gpt_icon":0},{"id":"2612269193","title":"每日卖空追踪 | 信达生物 02月20日卖空量成交89.25万股，卖空比例为16.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612269193","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612269193?lang=zh_cn&edition=full","pubTime":"2026-02-20 16:30","pubTimestamp":1771576224,"startTime":"0","endTime":"0","summary":"信达生物北京时间02月20日，涨1.85%，卖空量成交89.25万股，较上一交易日增加35.74%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220163255a70ccf63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220163255a70ccf63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2242644610.SGD","01801","HK0000165453.HKD","LU0455707207.USD","LU2097828557.USD","LU2097828631.EUR","LU2097828805.USD","LU2328871848.SGD","LU2097828474.EUR","BK1589","BK1161","LU2488822045.USD","BK1583","LU1969619763.USD","LU2097828714.EUR","LU0502904849.HKD"],"gpt_icon":0},{"id":"2612691982","title":"信达生物02月20日获主力加仓2004.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2612691982","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612691982?lang=zh_cn&edition=full","pubTime":"2026-02-20 16:15","pubTimestamp":1771575327,"startTime":"0","endTime":"0","summary":"02月20日, 信达生物股价涨1.85%，报收90.75元，成交金额5.2亿元，换手率0.33%，振幅1.80%，量比0.47。信达生物今日主力资金净流入2004.0万元，上一交易日主力净流入7449.9万元。该股近5个交易日上涨2.06%，主力资金累计净流入1.9亿元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入8883.4万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220161626a4b5db61&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220161626a4b5db61&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","BK1161","LU2097828474.EUR","LU2328871848.SGD","HK0000165453.HKD","01801","LU2097828631.EUR","BK1589","LU2097828805.USD","LU2097828557.USD","LU0455707207.USD","LU2097828714.EUR","BK1583","LU0502904849.HKD","LU1969619763.USD","LU2242644610.SGD"],"gpt_icon":0},{"id":"2612252506","title":"IO2.0争夺战打响，下一代肿瘤“药王”花落谁家？","url":"https://stock-news.laohu8.com/highlight/detail?id=2612252506","media":"药创新","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612252506?lang=zh_cn&edition=full","pubTime":"2026-02-20 15:00","pubTimestamp":1771570819,"startTime":"0","endTime":"0","summary":"下一代肿瘤“药王”争夺战打响！撰文丨粽哥2025下一代肿瘤“药王”，极有可能诞生于PD-1+X领域。以K药为代表的PD-1单抗，开启了一代IO治疗时代，但却存在耐药和冷肿瘤缺乏应答的问题。临床上，T细胞耗竭现象是导致免疫检查点获得性耐药的关键机制。TIGIT是经典免疫逃逸靶点，在多种淋巴细胞上表达，被认为是“下一个PD-1”。不过，PD-1/TIGIT双抗或有望打破TIGIT“难以成药”的魔咒。TIGIT和PD-1表达之间存在很强的相关性，特别是在肺癌的肿瘤浸","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602201513389541818d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602201513389541818d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","01530","BK1161","LU2476274720.SGD","LU2778985437.USD","LU0348735423.USD","LU1720050803.USD","LU0348827113.USD","02898","IE00B543WZ88.USD","LU0348784397.USD","09887","LU0417516738.SGD","LU2399975544.HKD","LU0348783233.USD","LU0348766576.USD","09995","LU0417516902.SGD","LU2488822045.USD","LU0348825331.USD","01801","IE00B5MMRT66.SGD","LU0634319403.HKD","BK1574","02616","LU0561508036.HKD","LU2476274308.USD","LU0540923850.HKD","LU1961090484.USD","IE00BPRC5H50.USD","LU0348767384.USD","LU1794554557.SGD","09926","LU0417516571.SGD","01877","01177"],"gpt_icon":1},{"id":"2612269164","title":"郭家耀：外围反复港股料争持 信达生物与礼来合作惹憧憬","url":"https://stock-news.laohu8.com/highlight/detail?id=2612269164","media":"AASTOCKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612269164?lang=zh_cn&edition=full","pubTime":"2026-02-20 09:18","pubTimestamp":1771550332,"startTime":"0","endTime":"0","summary":"另信达生物日前公告与礼来制药达成战略合作，推进肿瘤及免疫领域创新药物的全球研发进程。根据协定条款，信达生物将获得3.5亿美元首付款；在达成后续特定里程碑事件后，信达生物还有资格获得总额最高约85亿美元的研发、监管及商业化里程碑付款。此外，信达生物有权就各产品在大中华区以外的净销售额获得梯度的销售分成。信达生物拥有中国生物技术领域的领先地位，强大的商业化能力及与全球合作伙伴深度合作，令公司业绩及估值提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220101630a4b504f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220101630a4b504f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828474.EUR","HK0000165453.HKD","BK1589","LU2097828714.EUR","LU2097828805.USD","LU1969619763.USD","LU2097828631.EUR","LU0502904849.HKD","BK1583","LU2242644610.SGD","LU2488822045.USD","01801","BK1161","LU2328871848.SGD","LU2097828557.USD","LU0455707207.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":-0.0623},{"period":"1month","weight":0.0065},{"period":"3month","weight":-0.0956},{"period":"6month","weight":-0.1213},{"period":"1year","weight":0.9699},{"period":"ytd","weight":0.1161}],"compareEarnings":[{"period":"1week","weight":0.0082},{"period":"1month","weight":-0.043},{"period":"3month","weight":0.0298},{"period":"6month","weight":0.0619},{"period":"1year","weight":0.1228},{"period":"ytd","weight":0.039}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事研发、生产及销售治疗肿瘤、心血管及代谢（CVM）、自身免疫及眼科等重大疾病创新药物的投资控股公司。药物形式包括单克隆抗体、多特异性抗体、免疫细胞因子、抗体偶联药物（ADC）、细胞治疗及小分子药物等。该公司的主要产品包括达伯舒（信迪利单抗注射液）、达攸同（贝伐珠单抗注射液）、苏立信（阿达木单抗注射液）、达伯华（利妥昔单抗注射液）、达伯坦（佩米替尼片）等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.041076},{"month":2,"riseRate":0.75,"avgChangeRate":0.110526},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.021767},{"month":4,"riseRate":0.714286,"avgChangeRate":0.040816},{"month":5,"riseRate":0.428571,"avgChangeRate":0.027398},{"month":6,"riseRate":0.714286,"avgChangeRate":0.139165},{"month":7,"riseRate":0.428571,"avgChangeRate":0.010056},{"month":8,"riseRate":0.714286,"avgChangeRate":0.000214},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032182},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.02286},{"month":11,"riseRate":0.625,"avgChangeRate":0.079172},{"month":12,"riseRate":0.375,"avgChangeRate":0.024026}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}